Pay in 4 interest-free payments of $8.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
PubMed PMID: 27181927
InChi: InChI=1S/C22H21N8O8PS4
J Pediatr Hematol Oncol
486427-17-2
Hum Mol Genet
MLN-9708 - CAS# 1239908-20-3 60262 PubMed PMID: 27181927MLN 9708, also known as ixazomib citrate, CAS No. 1239908 20 3, is a prodrug of Ixazomib (MMLN 2238). MLN 9708 is an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. MLN 9708, after hydrolyzing to pharmacologically active MLN2238 (ixazomib), is a next generation proteasome inhibitor with demonstrated preclinical and clinical antimyeloma activity. MLN 9708, compared with bortezomib, has improved
US$ 61.00
US$ 175.00
US$ 17.00
US$ 235.50
US$ 138.00
US$ 64.99
US$ 14.00